What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Taking time off is nice, but returning for a July 4-shortened workweek is a bit discombobulating. Speaking of which, I’m landing in your inbox a day early because of the holiday. I hope you eat many hot dogs and watch amazing fireworks. Happy Birthday, America!

Let’s recap a wild week for Cassava Sciences

On Friday, the Justice Department charged the company’s chief scientific collaborator and paid consultant, Hoau-Yan Wang, with multiple counts of  fraud. According to the indictment, Wang, a professor at City University of New York, fabricated and falsified data pertaining to Cassava’s drug for Alzheimer’s disease, called simufilam, in order to obtain $16 million in grants from the National Institutes of Health for himself and Cassava.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In